Wednesday, July 12, 2023 10:38:15 AM
We must (begrudgingly) move on from the Covid trials and remember that Revive’s (patented) Bucillamine is medically effective for so much more than (only) Covid.
We challenge CEO Michael Frank to now bring home the bacon despite him and us long term investors facing loss fortunes on paper as it stands.
Disappointment aside, “Bonjour” from the South of France!
We challenge CEO Michael Frank to now bring home the bacon despite him and us long term investors facing loss fortunes on paper as it stands.
Disappointment aside, “Bonjour” from the South of France!
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
